3.60Open3.60Pre Close0 Volume2 Open Interest5.00Strike Price0.00Turnover374.11%IV-2.16%PremiumAug 16, 2024Expiry Date3.79Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8592Delta0.0276Gamma1.85Leverage Ratio-0.0417Theta0.0017Rho1.59Eff Leverage0.0048Vega
Terns Pharmaceuticals Stock Discussion
Larger Image: tradingview.com...
$Terns Pharmaceuticals(TERN.US)$
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
Terns Pharmaceuticals announced new preclinical data supporting their compound TERN-501 in combination with a GLP-1 receptor agonist for treating obesity. The data was presented at the ADA’s 84th Annual Scientific Sessions. TERN-501, a highly selective THR-...
Larger Image: tradingview.com...
$Terns Pharmaceuticals(TERN.US)$
Larger Image: tradingview.com...
$Terns Pharmaceuticals(TERN.US)$
NEWS
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
Larger Image: tradingview.com...
$Terns Pharmaceuticals(TERN.US)$
Larger Image: tradingview.com...
$Terns Pharmaceuticals(TERN.US)$
No comment yet